Lexaria Bioscience Corp

Research Lexaria Bioscience Corp (LEXX) on Bullrun: market cap USD 19.17M. Explore financials, valuation history, model signals, and stock context.

Key Metrics

Valuation Snapshot

latest market cap is USD 19.17M.

Five-year financial history

YearRevenueNet incomeFree cash flowGross marginDiluted EPSCashTotal debtEquity
FY2025USD 705.92K-USD 11.90M-USD 10.48M99.6%-0.66USD 1.80MUSD 101.92KUSD 2.99M
FY2024USD 464.28K-USD 5.80M-USD 5.00M99.0%-0.47USD 6.50MUSD 130.73KUSD 8.04M
FY2023USD 226.21K-USD 6.66M-USD 5.91M86.1%-1.01USD 1.35MUSD 155.07KUSD 3.04M
FY2022USD 255.40K-USD 7.27M-USD 4.93M71.9%n/aUSD 5.81MUSD 68.07KUSD 7.95M

Valuation history

YearSnapshot dateMarket capP/EDividend yieldAnnual dividend/share
20262026-08-25USD 19.17Mn/an/an/a
20252025-12-31USD 15.43Mn/an/an/a
20242024-12-31USD 36.65Mn/an/an/a
20232023-12-29USD 12.89Mn/an/an/a
20222022-12-30USD 14.64Mn/an/an/a
20212021-12-31USD 23.98Mn/an/an/a

About Lexaria Bioscience Corp

Lexaria Bioscience Corp. operates as a biotechnology company. The company offers its patented drug delivery-enabling platform technology, DehydraTECH, which combines active pharmaceutical ingredients (APIs) with specific long-chain fatty acid-rich triglyceride oils and carrier compounds that improve the way they enter the bloodstream, increasing their effectiveness and allowing for lower overall dosing for improved tolerability while promoting healthier oral ingestion methods.

Related stock research

Other Healthcare stocks

Frequently asked questions

What is Lexaria Bioscience Corp's market cap?

Lexaria Bioscience Corp's market capitalization is USD 19.17M.

What does Lexaria Bioscience Corp do?

Lexaria Bioscience Corp. operates as a biotechnology company. The company offers its patented drug delivery-enabling platform technology, DehydraTECH, which combines active pharmaceutical ingredients (APIs) with specific long-chain fatty acid-rich triglyceride oils and carrier compounds that improve the way they enter the bloodstream, increasing their effectiveness and allowing for lower overall dosing for improved tolerability while promoting healthier oral ingestion methods.